神经病学与神经康复学杂志2025，Vol.21Issue(1)：1-5,5.DOI:10.12022/jnnr.2024-0261
阿尔茨海默病诊断和分期新标准:生物标志物引领的精准医疗时代
New diagnostic and staging criteria for Alzheimer's disease:the era of precision medicine led by biomarkers
摘要
Abstract
Alzheimer's disease(AD)is a common neurodegenerative disease.With the aging of the global population,the number of patients with AD is constantly increasing,bringing heavy burdens to the patients,families and society.The early and accurate diagnosis of AD has always been a hot and difficult issue.In recent years,with the advancement of scientific research,there have been significant achievements in the study of imaging and biofluid biomarkers of AD,such as the new breakthroughs in PET imaging technology in detecting amyloid and Tau protein deposition in the brain,and the discovery and application of blood biomarkers among biofluid biomarkers.In 2024,The National Institute on Aging and Alzheimer's Association(NIA-AA)updated the diagnostic and staging guidelines for AD,namely the Revised Criteria for Diagnosis and Staging of Alzheimer's Disease(2024).This paper aims to interpret the guidelines and review the progress in the diagnosis and staging of AD,providing more accurate diagnostic basis for clinicians and helping researchers to further explore the pathogenesis of AD.关键词
阿尔茨海默病/诊断/分期/生物标志物/精准医学/指南Key words
Alzheimer's disease/Diagnosis/Staging/Biomarker/Precision medicine/Guideline引用本文复制引用
岳玲,江叶昊..阿尔茨海默病诊断和分期新标准:生物标志物引领的精准医疗时代[J].神经病学与神经康复学杂志,2025,21(1):1-5,5.基金项目
科技创新2030重大项目"脑科学与类脑研究"(2022ZD0213100) Science and Technology Innovation 2030 Major Project:Neuroscience and Brain-like Research(2022ZD0213100) （2022ZD0213100）
